pindolol has been researched along with Depression, Involutional in 17 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty outpatients with major depressive disorder (DSM-IV criteria) recruited between December 2002 and November 2005 were randomly assigned to receive citalopram + pindolol (5 mg tid) or citalopram + placebo for 6 weeks in a double-blind randomized clinical trial." | 3.85 | Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. ( Álvarez, E; Artigas, F; Ballesteros, J; de Diego-Adeliño, J; Oller, S; Pérez, V; Portella, MJ; Puigdemont, D; Santos, B, 2011) |
| "Pindolol has been widely investigated as an augmenter of antidepressant drug response." | 2.77 | A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression. ( Bech, P; Lunde, M; Martiny, K; Plenge, P, 2012) |
| "Forty-two outpatients with DSM-IV major depressive disorder who had an insufficient response to an adequate trial of an SSRI (fluoxetine, paroxetine, or sertraline) were randomly assigned to pindolol, 2." | 2.71 | Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. ( Anand, A; Berman, RM; Charney, DS; Lynch-Colonese, K; Perry, EB; Sanacora, G, 2004) |
| "Major depressive disorder is a severe, disabling disorder that affects around 4." | 2.61 | Monoaminergic system and depression. ( Berrocoso, E; González-Saiz, F; Mico, JA; Perez-Caballero, L; Romero-López-Alberca, C; Torres-Sanchez, S, 2019) |
| " It is also suggested that positron emission tomography may be used to define therapeutic dosing early on in the process of clinical evaluation of new treatment strategies." | 2.41 | Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. ( Broft, A; Laruelle, M; Martinez, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perez-Caballero, L | 1 |
| Torres-Sanchez, S | 1 |
| Romero-López-Alberca, C | 1 |
| González-Saiz, F | 1 |
| Mico, JA | 1 |
| Berrocoso, E | 1 |
| Portella, MJ | 1 |
| de Diego-Adeliño, J | 1 |
| Ballesteros, J | 1 |
| Puigdemont, D | 1 |
| Oller, S | 1 |
| Santos, B | 1 |
| Álvarez, E | 2 |
| Artigas, F | 3 |
| Pérez, V | 2 |
| Terao, T | 1 |
| Martiny, K | 1 |
| Lunde, M | 1 |
| Bech, P | 1 |
| Plenge, P | 2 |
| Mellerup, ET | 1 |
| Perry, EB | 1 |
| Berman, RM | 1 |
| Sanacora, G | 1 |
| Anand, A | 1 |
| Lynch-Colonese, K | 1 |
| Charney, DS | 1 |
| Sokolski, KN | 1 |
| Conney, JC | 1 |
| Brown, BJ | 1 |
| DeMet, EM | 1 |
| Celada, P | 1 |
| Puig, M | 1 |
| Amargós-Bosch, M | 1 |
| Adell, A | 1 |
| Segrave, R | 1 |
| Nathan, PJ | 1 |
| Maes, M | 2 |
| Westenberg, H | 1 |
| Vandoolaeghe, E | 2 |
| Demedts, P | 1 |
| Wauters, A | 1 |
| Neels, H | 1 |
| Meltzer, HY | 1 |
| Verkerk, R | 1 |
| Lin, A | 1 |
| Scharpé, S | 1 |
| Räsänen, P | 1 |
| Hakko, H | 1 |
| Tiihonen, J | 1 |
| Martinez, D | 1 |
| Broft, A | 1 |
| Laruelle, M | 1 |
| Puiigdemont, D | 1 |
| Gilaberte, I | 1 |
| Zanardi, R | 2 |
| Serretti, A | 2 |
| Rossini, D | 2 |
| Franchini, L | 1 |
| Cusin, C | 2 |
| Lattuada, E | 2 |
| Dotoli, D | 1 |
| Smeraldi, E | 2 |
| Rabiner, EA | 1 |
| Bhagwagar, Z | 1 |
| Gunn, RN | 1 |
| Sargent, PA | 1 |
| Bench, CJ | 1 |
| Cowen, PJ | 1 |
| Grasby, PM | 1 |
| Lilli, R | 1 |
| Lorenzi, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder[NCT00931775] | Phase 2 | 30 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Short Term Double Blind Randomised Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression[NCT00159146] | 31 participants (Actual) | Interventional | 2002-08-31 | Terminated (stopped due to lack of participants fulfilling inclusion criteria) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pindolol and Depression, Involutional
| Article | Year |
|---|---|
Monoaminergic system and depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Biogenic Monoamines; Buspirone; Depressive Disorder, Ma | 2019 |
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Antidepressive Agents, Second-Generation; | 2011 |
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
Topics: Autoreceptors; Depressive Disorder, Major; Humans; Pindolol; Receptor, Serotonin, 5-HT1A; Receptors, | 2004 |
Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression.
Topics: Adrenergic beta-Antagonists; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combinat | 2005 |
Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Topics: Animals; Brain; Cerebrovascular Circulation; Clinical Trials as Topic; Depressive Disorder, Major; D | 2000 |
9 trials available for pindolol and Depression, Involutional
| Article | Year |
|---|---|
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Antidepressive Agents, Second-Generation; | 2011 |
A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
Topics: Adult; Aged; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Desvenlafaxine Succinat | 2012 |
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Connecticut; Cross-Over Studies; Depressive Disorder, Majo | 2004 |
Once-daily high-dose pindolol for SSRI-refractory depression.
Topics: Adult; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Pindolol; Ser | 2004 |
Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Rel | 1997 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; | 1998 |
Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.
Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind | 2001 |
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Carrier Proteins; Delusions; Depressive Disorder, Ma | 2001 |
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Antimanic Agents; Depressive | 2002 |
4 other studies available for pindolol and Depression, Involutional
| Article | Year |
|---|---|
Can pindolol really enhance antidepressant effect?
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disord | 2011 |
Pindolol and the acceleration of the antidepressant response.
Topics: Depressive Disorder, Major; Drug Administration Schedule; Humans; Pindolol; Selective Serotonin Reup | 2003 |
Mitchell B. Balter Award--1998. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients.
Topics: Adrenergic beta-Antagonists; Atenolol; Depressive Disorder, Major; Disability Evaluation; Drug Thera | 1999 |
Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low.
Topics: Adult; Brain; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Sche | 2001 |